- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Survey: Half of those with chronic disease suffer from chronic sleep problems
- Report: Dietary supplements utilized as preventive health care can save health system tens of billions of dollars
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
NEW YORK — Japan-based Takeda Pharmaceutical may acquire Switzerland’s Nycomed for $12 billion, according to published reports.
Reuters reported Thursday that Takeda was in talks to buy Nycomed in order to expand its presence in the European market. Most of Takeda’s business is in Asia and the United States.
Nycomed makes treatments for such diseases as chronic obstructive pulmonary disease, chronic pain, osteoporosis and others.